{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:11:56Z","timestamp":1792552316102,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40265-025-02264-z","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T05:32:19Z","timestamp":1763962339000},"page":"127-133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tolebrutinib: First Approval"],"prefix":"10.1007","volume":"86","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"101359","key":"2264_CR1","first-page":"1","volume":"54","author":"M Trojano","year":"2025","unstructured":"Trojano M, Paolicelli D. Targeting smouldering neuroinflammation in multiple sclerosis: insights from tolebrutinib clinical trials. Lancet Reg Health Eur. 2025;54(101359):1\u20132.","journal-title":"Lancet Reg Health Eur"},{"key":"2264_CR2","unstructured":"Emirates News Agency-WAM. Emirates Drug Establishment grants global first approval for \u2018Tolebrutinib\u2019 [media release]. 26 Aug 2025. http:\/\/www.wam.ae."},{"key":"2264_CR3","unstructured":"Sanofi. CENRIFKI\u00ae (tolebrutinib) film coated tablets, for oral use: UAE package leaflet. 2025."},{"key":"2264_CR4","unstructured":"Sanofi. Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis [media release]. 22 Sep 2025. http:\/\/www.sanofi.com."},{"key":"2264_CR5","unstructured":"Sanofi. Sanofi, Principia agree to develop multiple sclerosis drug candidate [media release]. 9 Nov 2017. http:\/\/en.sanofi.com."},{"key":"2264_CR6","unstructured":"Sanofi. Sanofi to acquire Principia Biopharma [media release]. 17 Aug 2020. http:\/\/www.sanofi.com."},{"key":"2264_CR7","unstructured":"Sanofi. Sanofi completes Principia Biopharma Inc. acquisition [media release]. 28 Sep 2020. http:\/\/www.sanofi.com."},{"issue":"2","key":"2264_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/cts.13162","volume":"15","author":"TD Owens","year":"2022","unstructured":"Owens TD, Smith PF, Redfern A, Xing Y, Shu J, Karr DE, et al. Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clin Transl Sci. 2022;15(2):442\u201350. https:\/\/doi.org\/10.1111\/cts.13162.","journal-title":"Clin Transl Sci"},{"issue":"19","key":"2264_CR9","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","volume":"392","author":"RJ Fox","year":"2025","unstructured":"Fox RJ, Bar-Or A, Traboulsee A, et al. Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis. N Engl J Med. 2025;392(19):1883\u201392.","journal-title":"N Engl J Med"},{"issue":"2","key":"2264_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40268-024-00468-4","volume":"24","author":"TJ Turner","year":"2024","unstructured":"Turner TJ, Brun P, Gruber RC, et al. Comparative CNS pharmacology of the Bruton\u2019s tyrosine kinase (BTK) inhibitor tolebrutinib versus other BTK inhibitor candidates for treating multiple sclerosis. Drugs R D. 2024;24(2):263\u201374.","journal-title":"Drugs R D"},{"issue":"2","key":"2264_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13693","volume":"17","author":"M-J Cabanis","year":"2024","unstructured":"Cabanis M-J, Nicolas O, Vitse O, Cabanis M-J, Jan C, Brun P, et al. A phase I trial assessing the safety, pharmacokinetics, cerebrospinal fluid penetrance, and food effect of BTK inhibitor tolebrutinib in healthy volunteers. Clin Transl Sci. 2024;17(2):e13693. https:\/\/doi.org\/10.1111\/cts.13693.","journal-title":"Clin Transl Sci"},{"issue":"Suppl 1","key":"2264_CR12","first-page":"11","volume":"30","author":"MI Gaitan","year":"2024","unstructured":"Gaitan MI, Raza S, Donnay C, et al. Primary outcome of a phase 2 clinical trial of tolebrutinib, a brain-penetrant BTK inhibitor, for the modulation of chronically inflamed white matter lesions in MS [abstract no. LB1.2]. Mult Scler J. 2024;30(Suppl 1):11.","journal-title":"Mult Scler J"},{"issue":"8","key":"2264_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40261-023-01296-1","volume":"43","author":"O Nicolas","year":"2023","unstructured":"Nicolas O, Moliner P, Soubayrol P, et al. Absorption, metabolism, and excretion of [14C]-tolebrutinib after oral administration in humans, contribution of the metabolites to pharmacological activity. Clin Drug Investig. 2023;43(8):653\u201365.","journal-title":"Clin Drug Investig"},{"issue":"19","key":"2264_CR14","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","volume":"392","author":"J Oh","year":"2025","unstructured":"Oh J, Arnold DL, Cree BAC, et al. Tolebrutinib versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2025;392(19):1893\u2013904.","journal-title":"N Engl J Med"},{"issue":"9","key":"2264_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","volume":"20","author":"DS Reich","year":"2021","unstructured":"Reich DS, Arnold DL, Vermersch P, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20(9):729\u201338.","journal-title":"Lancet Neurol"},{"issue":"3","key":"2264_CR16","doi-asserted-by":"publisher","DOI":"10.1212\/WN9.0000000000000028","volume":"1","author":"J Oh","year":"2025","unstructured":"Oh J, Fox RJ, Arnold DL, Syed S, Dukovic D, Vargas WS, et al. Tolebrutinib phase 2b long-term extension study: two-year safety, MRI, and clinical efficacy outcomes in patients with relapsing multiple sclerosis. Neurol Open Access. 2025;1(3):e000028. https:\/\/doi.org\/10.1212\/WN9.0000000000000028.","journal-title":"Neurol Open Access"},{"issue":"Suppl 3","key":"2264_CR17","first-page":"334","volume":"29","author":"J Oh","year":"2023","unstructured":"Oh J, Reich D, Traboulsee A, et al. Safety and clinical efficacy outcomes from the long-term extension study of tolebrutinib in participants with relapsing multiple sclerosis: 3-year results [abstract no. P278\/1470 plus poster]. Mult Scler J. 2023;29(Suppl 3):334\u20135.","journal-title":"Mult Scler J"},{"issue":"Suppl 1","key":"2264_CR18","first-page":"63","volume":"32","author":"R Fox","year":"2025","unstructured":"Fox R, Reich D, Traboulsee A, et al. Baseline characteristics in the tolebrutinib phase 3 primary progressive multiple sclerosis PERSEUS clinical trial [abstract no. EPV-626 plus poster]. Eur J Neurol. 2025;32(Suppl 1):63.","journal-title":"Eur J Neurol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02264-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02264-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02264-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T02:00:13Z","timestamp":1768356013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02264-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2264"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02264-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}